PT  - JOURNAL ARTICLE
ED  - ,
TI  - Correction: Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
AID  - 10.1136/jitc-2021-003188corr1
DP  - 2021 Nov 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e003188corr1
VI  - 9
IP  - 11
4099  - http://jitc.bmj.com/content/9/11/e003188corr1.short
4100  - http://jitc.bmj.com/content/9/11/e003188corr1.full
SO  - J Immunother Cancer2021 Nov 01; 9